Cargando…

Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients

BACKGROUND: Osteogenesis imperfecta (OI) is a rare bone disorder. In 90% of cases, OI is caused by mutations in the COL1A1/2 genes, which code procollagen α1 and α2 chains. The main aim of the current research was to identify the mutational spectrum of COL1A1/2 genes in Estonian patients. The small...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhytnik, Lidiia, Maasalu, Katre, Reimann, Ene, Prans, Ele, Kõks, Sulev, Märtson, Aare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558703/
https://www.ncbi.nlm.nih.gov/pubmed/28810924
http://dx.doi.org/10.1186/s40246-017-0115-5
_version_ 1783257430899032064
author Zhytnik, Lidiia
Maasalu, Katre
Reimann, Ene
Prans, Ele
Kõks, Sulev
Märtson, Aare
author_facet Zhytnik, Lidiia
Maasalu, Katre
Reimann, Ene
Prans, Ele
Kõks, Sulev
Märtson, Aare
author_sort Zhytnik, Lidiia
collection PubMed
description BACKGROUND: Osteogenesis imperfecta (OI) is a rare bone disorder. In 90% of cases, OI is caused by mutations in the COL1A1/2 genes, which code procollagen α1 and α2 chains. The main aim of the current research was to identify the mutational spectrum of COL1A1/2 genes in Estonian patients. The small population size of Estonia provides a unique chance to explore the collagen I mutational profile of 100% of OI families in the country. METHODS: We performed mutational analysis of peripheral blood gDNA of 30 unrelated Estonian OI patients using Sanger sequencing of COL1A1 and COL1A2 genes, including all intron-exon junctions and 5′UTR and 3′UTR regions, to identify causative OI mutations. RESULTS: We identified COL1A1/2 mutations in 86.67% of patients (26/30). 76.92% of discovered mutations were located in the COL1A1 (n = 20) and 23.08% in the COL1A2 (n = 6) gene. Half of the COL1A1/2 mutations appeared to be novel. The percentage of quantitative COL1A1/2 mutations was 69.23%. Glycine substitution with serine was the most prevalent among missense mutations. All qualitative mutations were situated in the chain domain of pro-α1/2 chains. CONCLUSION: Our study shows that among the Estonian OI population, the range of collagen I mutations is quite high, which agrees with other described OI cohorts of Northern Europe. The Estonian OI cohort differs due to the high number of quantitative variants and simple missense variants, which are mostly Gly to Ser substitutions and do not extend the chain domain of COL1A1/2 products.
format Online
Article
Text
id pubmed-5558703
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55587032017-08-16 Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients Zhytnik, Lidiia Maasalu, Katre Reimann, Ene Prans, Ele Kõks, Sulev Märtson, Aare Hum Genomics Primary Research BACKGROUND: Osteogenesis imperfecta (OI) is a rare bone disorder. In 90% of cases, OI is caused by mutations in the COL1A1/2 genes, which code procollagen α1 and α2 chains. The main aim of the current research was to identify the mutational spectrum of COL1A1/2 genes in Estonian patients. The small population size of Estonia provides a unique chance to explore the collagen I mutational profile of 100% of OI families in the country. METHODS: We performed mutational analysis of peripheral blood gDNA of 30 unrelated Estonian OI patients using Sanger sequencing of COL1A1 and COL1A2 genes, including all intron-exon junctions and 5′UTR and 3′UTR regions, to identify causative OI mutations. RESULTS: We identified COL1A1/2 mutations in 86.67% of patients (26/30). 76.92% of discovered mutations were located in the COL1A1 (n = 20) and 23.08% in the COL1A2 (n = 6) gene. Half of the COL1A1/2 mutations appeared to be novel. The percentage of quantitative COL1A1/2 mutations was 69.23%. Glycine substitution with serine was the most prevalent among missense mutations. All qualitative mutations were situated in the chain domain of pro-α1/2 chains. CONCLUSION: Our study shows that among the Estonian OI population, the range of collagen I mutations is quite high, which agrees with other described OI cohorts of Northern Europe. The Estonian OI cohort differs due to the high number of quantitative variants and simple missense variants, which are mostly Gly to Ser substitutions and do not extend the chain domain of COL1A1/2 products. BioMed Central 2017-08-15 /pmc/articles/PMC5558703/ /pubmed/28810924 http://dx.doi.org/10.1186/s40246-017-0115-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Zhytnik, Lidiia
Maasalu, Katre
Reimann, Ene
Prans, Ele
Kõks, Sulev
Märtson, Aare
Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title_full Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title_fullStr Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title_full_unstemmed Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title_short Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients
title_sort mutational analysis of col1a1 and col1a2 genes among estonian osteogenesis imperfecta patients
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558703/
https://www.ncbi.nlm.nih.gov/pubmed/28810924
http://dx.doi.org/10.1186/s40246-017-0115-5
work_keys_str_mv AT zhytniklidiia mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients
AT maasalukatre mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients
AT reimannene mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients
AT pransele mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients
AT kokssulev mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients
AT martsonaare mutationalanalysisofcol1a1andcol1a2genesamongestonianosteogenesisimperfectapatients